An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Korábbi kezelés

• Major surgery within 8 weeks of screening
• Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline
• Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline
• Received live or live-attenuated vaccine within 4 weeks of baseline
• Prior receipt of RPT193

Más betegség

• Uncontrolled diabetes
• Stage III or IV cardiac failure
• Severe renal condition

Egyéb

• Uncontrolled moderate-to-severe asthma

• Clinically confirmed diagnosis of active atopic dermatitis (AD), according to the revised Hanifin and Rajka criteria
• 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening
• inadequate response to a ≥1 month treatment with topical medications
• Atopic dermatitis covering ≥10% of the body surface area
• EASI score ≥16
• Validated Investigator Global Assessment (VIGA) ≥3
• Use of emollient(s) at least 2x daily for 1 week prior to baseline
• Negative coronavirus disease (COVID)-19 results at screening